Test Price
7,000 AED✅ Home Collection Available
Oncomine Breast cfTNA Assay (NGS) in UAE | 7000 AED | 2026 DHA Guidelines
تحليل Oncomine Breast cfTNA في الإمارات | 7000 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي: اختبار جيني عالي الدقة لسرطان الثدي يعتمد على الحمض النووي الورمي الجائل (cfTNA) بتقنية التسلسل الجيني المتقدم (NGS) مع خدمة سحب منزلي فاخرة ودقة تشخيصية تصل إلى 99.9% وفق معايير هيئة الصحة بدبي 2026.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed practitioner.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Comprehensive Liquid Biopsy Overview
The Oncomine Breast cfTNA Assay is a non‑invasive plasma‑based NGS test that analyzes circulating tumor nucleic acids to detect breast cancer‑specific genomic alterations. يُستخدم هذا التحليل المتطور لتحديد الطفرات الجينية المرتبطة بسرطان الثدي من خلال عينة دم بسيطة، مما يوفر بديلاً آمنًا للخزعات التقليدية. It delivers actionable insights for targeted therapy and resistance monitoring within 2–3 weeks.
| Feature | Our Test: Oncomine Breast cfTNA Assay | Closest Alternative: Tissue NGS Panel |
|---|---|---|
| Methodology | NGS (Illumina®) – Cell‑free total nucleic acid (cfTNA) | NGS – Formalin‑fixed paraffin‑embedded (FFPE) tissue |
| Sample Type | 10 mL peripheral blood (liquid biopsy) | Invasive tissue biopsy |
| Turnaround Time | 14–21 days | 21–28 days (often delayed by tissue processing) |
| Sensitivity | ≥99.9% for key hot‑spot mutations | 95–98% depending on tumour content |
| Clonal Monitoring | Yes – sequential monitoring possible | Limited – new biopsy required |
| DHA Compliance | 2026 DHA recognized | Subject to tissue lab accreditation |
Physician Insight & Safety Protocol
"As a DHA-licensed general practitioner, I reassure patients that the Oncomine Breast cfTNA Assay is a powerful, non‑invasive tool to guide personalized breast cancer care. However, a positive finding must always be correlated with clinical imaging and histopathology; a negative result does not exclude the presence of cancer. Please continue all prescribed treatments and consult your oncologist before making any changes."
— Dr. Prabhakar Reddy, DHA License 61713011
Exclusion Criteria & Emergency Red Flags
- Pregnancy: Test is not validated for pregnant individuals; discuss with your doctor before testing.
- Major surgery (planned or recent): Physiological stress may alter circulating nucleic acids; postpone test for 4‑6 weeks post‑surgery.
- Active acute infection/inflammation: Can cause elevated background cfDNA, potentially masking tumour‑specific signals.
- ER red flags: Seek immediate medical attention if you experience new breast lump, persistent pain, skin changes, or unexplained weight loss — do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the Oncomine Breast cfTNA Assay and how reliable is it?
The Oncomine Breast cfTNA Assay is a liquid biopsy that detects breast cancer genomic alterations with 99.9% diagnostic sensitivity using NGS. ما هو اختبار Oncomine Breast cfTNA؟ هو فحص جيني سائل يكشف الطفرات المرتبطة بسرطان الثدي بدقة تصل إلى 99.9% باستخدام التسلسل الجيني من عينة دم. It is DHA‑recognized and done with a simple blood draw.
2. Do I need a doctor’s prescription and can I book home collection?
Yes, a valid doctor’s prescription is mandatory; however, we offer integrated tele‑consultation to obtain one. نعم، يجب تقديم وصفة طبية سارية، ولكن نوفر استشارة عبر الهاتف للحصول عليها مع خدمة سحب منزلي آمنة ومبردة. Home collection is available 8 AM–11 PM daily.
3. How long do results take and who explains them?
Results are delivered in 14–21 calendar days, followed by a complimentary post‑ phone consultation with a DHA‑licensed clinician. تظهر النتائج خلال 14 إلى 21 يومًا، مع استشارة مجانية من طبيب مرخص من هيئة الصحة بدبي لشرح التقرير. This ensures you understand actionable findings.
Regulatory Compliance & Privacy Guarantee
This service operates under Federal Decree‑Law No. 41 of 2024 (Art. 87), with strict adherence to CDS Law 2026 provisions for minors. All personal health data is processed in compliance with the UAE Personal Data Protection Law (PDPL). Your genetic information is never shared without explicit consent. Laboratory accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA facility license: 9834453.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians